Does disease activity at start of biologic therapy influence work-loss in RA patients?

Tor O Olofsson; Kari Johansson; Jonas K Eriksson; Ronald van Vollenhoven; Heather Miller; Ingemar Petersson; Johan Askling; Martin Neovius

doi:10.1093/rheumatology/kev407

Does disease activity at start of biologic therapy influence work-loss in RA patients?

Tor O Olofsson, Kari Johansson, Jonas K Eriksson, Ronald van Vollenhoven, Heather Miller, Ingemar Petersson, Johan Askling, Martin Neovius

Karolinska Institute

Research output: Contribution to journal › Article › peer-review

Abstract

To compare work-loss in RA patients starting their first biologic with high vs moderate disease activity.

Original language	English
Journal	Rheumatology (Oxford, England)
Early online date	2015 Dec 18
DOIs	https://doi.org/10.1093/rheumatology/kev407
Publication status	Published - 2015

Subject classification (UKÄ)

Clinical Medicine

Access to Document

10.1093/rheumatology/kev407

http://www.ncbi.nlm.nih.gov/pubmed/26683196?dopt=Abstract

1 Doctoral Thesis (compilation)

Anti-TNF therapy in rheumatoid arthritis. Effects on and predictors of work disability
Olofsson, T. O., 2016, Department of Clinical Sciences, Lund University. 108 p.
Research output: Thesis › Doctoral Thesis (compilation)

Cite this

@article{e25d853b65754eb6b8050ccdedcf1159,

title = "Does disease activity at start of biologic therapy influence work-loss in RA patients?",

abstract = "To compare work-loss in RA patients starting their first biologic with high vs moderate disease activity.",

author = "Olofsson, {Tor O} and Kari Johansson and Eriksson, {Jonas K} and {van Vollenhoven}, Ronald and Heather Miller and Ingemar Petersson and Johan Askling and Martin Neovius",

year = "2015",

doi = "10.1093/rheumatology/kev407",

language = "English",

journal = "Rheumatology (Oxford, England)",